This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sheikh, J S Articles by Hess, E V Search for Related Content PubMed PubMed Citation Articles by Sheikh, J S Articles by Hess, E V Social Bookmarking                         What's this?

Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis

G S Retzinger

E V Hess

Departments of Medicine and Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteonecrosis (ON). Twenty-six patients with SLE were studied. Fifteen of these had ON and 11 did not. The latter were used as control subjects. Various coagulation analytes including antithrombin III (ATIII) activity, protein C activity, protein S activity, a2-antiplasmin activity, anticardiolipin antibodies (aCL), plasminogen activator inhibitor (PAI-1) activity and tissue type plasminogen activator (tPA) antigen were measured using citrated plasma samples from the patients. A significant proportion (80%) of patients had at least one laboratory abnormality that has been associated with a thrombotic predisposition. ON was significantly associated with elevated levels of PAI-1 activity; it was also associated with elevated PAI-1/tPA ratio. There was no association between ON of SLE and abnormalities of the other measured coagulation analytes. These results suggest that defective fibrinolysis seems to be operative in the pathogenesis of ON associated with SLE. The defect appears to involve an imbalance between tPA and its inhibitor, PAI-1. This imbalance could represent an important risk factor in the pathogenesis of ON.

Key Words: osteonecrosis • fibrinolysis • systemic lupus erythematosus

Lupus, Vol. 7, No. 1, 42-48 (1998)
DOI: 10.1191/096120398678919732


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.C.M.S. Fialho, E. Bonfa, L.F. Vitule, E. D'Amico, V. Caparbo, S. Gualandro, and R.M.R. Pereira Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus Lupus, April 1, 2007; 16(4): 239 - 244. [Abstract] [PDF]

				J Calvo-Alen, G McGwin, S Toloza, M Fernandez, J M Roseman, H M Bastian, E J Cepeda, E B Gonzalez, B A Baethge, B J Fessler, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study Ann Rheum Dis, June 1, 2006; 65(6): 785 - 790. [Abstract] [Full Text] [PDF]

				K. Miyanishi, T. Yamamoto, T. Irisa, G. Motomura, S. Jingushi, K. Sueishi, and Y. Iwamoto Effects of different corticosteroids on the development of osteonecrosis in rabbits Rheumatology, March 1, 2005; 44(3): 332 - 336. [Abstract] [Full Text] [PDF]

				K Oinuma, Y Harada, Y Nawata, K Takabayashi, I Abe, K Kamikawa, and H Moriya Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment Ann Rheum Dis, December 1, 2001; 60(12): 1145 - 1148. [Abstract] [Full Text] [PDF]